Notícias

Novo Nordisk said on Thursday it has ‌identified a security incident involving ‌unauthorized access to a limited number ​of internal IT systems. The company's core business operations are not impacted and remain ​up ‌and running, it added.

Scott Galloway and Ed Elson laid out the math on Prof G Markets and it should make every fast food shareholder uneasy: roughly 30 million Americans, about 1 in 8 US adults, are now on GLP-1s, and the drugs are reducing fast food’s addressable market by an estimated 27-30%. This is structural, not cyclical: appetite, ... The GLP-1 stock nobody is pricing in isn’t a drugmaker

Find insight on Big European pharmaceutical companies, GSK, Kossan Rubber Industries and more in the latest Market Talks covering the health care sector.

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

European equities traded in the US as American depositary receipts were tracking lower late Tuesday

MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.

By Chris Prentice and Maggie Fick NEW YORK/LONDON, June 10 (Reuters) - Eli Lilly has solidified its leading position in the booming market for obesity drugs ahead of a wave of possible new entrants to

Recent performance snapshot Novo Nordisk (CPSE:NOVO B) has seen mixed share performance, with the stock down 0.7% over the past day and 2.8% over the past week, but up 8.1% over the past 3 months. Over longer periods the picture is more challenging, with the stock down over the past month, year to date, and past year, while still showing a gain over the past 5 years. This provides important context before looking at fundamentals. See our latest analysis for Novo Nordisk. At a share price of...

Novo Nordisk’s Ibrahim Kamstrup-Akkaoui outlines how the Danish GLP-1 giant is embedding AI into its clinical foundation.

The milestone shows strong early demand as Novo competes with Lilly in oral weight-loss drugs.

AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.

LLY stock hits a new all-time high as data from phase III studies show Foundayo outperforming rivals and retatrutide delivering strong weight-loss and diabetes results.

Healthcare ETFs are gaining attention as Middle East tensions and market volatility boost demand for defensive sectors.

Lilly’s Foundayo outperformed existing treatments on blood sugar control and weight loss in type 2 diabetes patients in three late-stage trials.

Novo's CEO says semaglutide could push the company beyond obesity and diabetes into longevity and appearance-related medicine.

Zealand Pharma's stock is cratering today after disappointing results from a late-stage trial of its GLP-1 dual-receptor agonist drug.

Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that could validate its multi-pathway liver strategy.

Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 data and a planned Phase III launch shaping its path.

ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.

Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into immunology and neurology.

Is NVO a good stock to buy? We came across a bullish thesis on Novo Nordisk A/S on Hated Moats’s Substack by Hated Moats Investors. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S’s share was trading at $42.96 as of June 5th. NVO’s trailing and forward P/E were 10.09 and 12.77 […]

European equities traded in the US as American depositary receipts kicked off the week higher late M

NVO says real-world data show Ozempic 2 mg matches Eli Lilly's Mounjaro on glucose control and is linked to a higher likelihood of meaningful weight loss.

NVO's oral Wegovy launch is off to a blistering start, topping 3 million prescriptions in five months and drawing many first-time GLP-1 users.

Novo Nordisk (NYSE:NVO) has entered a clinical supply agreement with Veru to test a combination of Wegovy and enobosarm in an obesity trial focused on older adults. The company also presented new semaglutide data at the American Diabetes Association Scientific Sessions on health effects beyond weight loss. The stock most recently closed at $42.96, with the share price down 18.0% year to date and down 41.2% over the past year. Novo Nordisk, trading under NYSE:NVO, is drawing attention as it...

More than 80% of new Wegovy pill prescriptions are for patients who had never previously taken a GLP-1 drug

At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.

Novo Nordisk (NYSE:NVO) shares fell 3% on Monday as investors digested new data and commercial updates presented by the company during the American Diabetes Association (ADA) conference over the weekend. While the event featured encouraging clinical findings for Novo’s next-generation diabetes therapies, analysts said the overall readout provided little that would materially alter the company’s near-term competitive position.

The weight-loss rivals provided positive updates on their obesity treatments but to differing reactions among investors.

Momentum is building to bring a next-generation weight loss drug to market, which could set up these three biotechs to strike a deal with a larger pharma.